Quintiles and Kaiser Permanente’s Southern California Permanente Medical Group (SCPMG) has signed an agreement to accelerate the development of new medicines.

SCPMG will join Quintile’s prime sites in the University of Pretoria, South Africa; Queen Mary’s College in London, UK; and the Washington Hospital Center in Washington DC, US, to carry out clinical research.

Quintiles said biopharmaceutical companies are expected to benefit from the collaboration as the partners offer clinical and research expertise, thereby reducing complexity and accelerating trials.